Coverage
-
April 17, 2026
A Manhattan federal judge Friday refused to block Johnson & Johnson from advertising its prostate cancer drug as having a lower risk of death compared with Bayer's medication, saying Bayer has not shown it is likely to succeed on its claims that its rival's advertising campaign is false or misleading.
1 other articles on this case.
View all »